Rheumatoid arthritis (RA)
Jaime Guzman, MD, MSc
University of British Columbia and BC Children's Hospital
Vancouver, British Columbia, Canada
Disclosure information not submitted.
Kulveer Mankia, MD
University of Leeds
Leeds, United Kingdom
Disclosure(s): Abbvie: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Deepcure: Consultant (Ongoing); Galapagos: Consultant (Terminated); Lilly: Consultant (Terminated); Serac Healthcare: Consultant (Ongoing); Zura Bio: Consultant (Ongoing)
Rheumatoid Arthritis (RA) has a preclinical period of development that may be targeted for prevention. However, current models for risk stratification for future RA are limited. This session will highlight ACR/EULAR Task Force efforts to develop robust risk stratification models for future RA that can be applied in clinical trials. This will be of great interest to researchers and clinicians caring for RA, as well as to rheumatologists who are contemplating similar models in other rheumatic diseases.
Speaker: Annette van der Helm-van Mil, professor – LUMC
Speaker: Kevin Deane, MD,PhD – University of Colorado Denver Anschutz Medical Campus
Speaker: Andrew Cope, MD;PhD – King's College London